Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing
Key PointsAndrew Guggenhime surrendered 2,705 shares at $61.18 per share on August 31 and September 2, representing a transaction value of $165,492.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.